Neuralink to Trial Brain Implants for Speech Disabilities

• The trial targets individuals who have lost the ability to speak, allowing them to bypass keyboards and convert imagined speech directly from brain signals to voice output
• FDA's Breakthrough Device designation for the speech application will accelerate development, assessment, and review processes
• Neuralink has implanted 12 people globally with over 15,000 hours of cumulative use, with the first patient already using it for gaming, internet browsing, and cursor control

Summary

Elon Musk's Neuralink plans to launch a clinical trial in October targeting individuals with speech impairments, aiming to enable direct brain-to-text communication. The company's president, Dongjin "D.J." Seo, announced the initiative during a presentation at the Korea Advanced Institute of Science and Technology in Seoul, explaining that the technology will allow users to translate imagined speech directly into voice without keyboards.

Key Developments:

The U.S. Food and Drug Administration has granted Neuralink's device Breakthrough Device designation for speech applications, potentially accelerating the development and regulatory review process.

Neuralink commenced human trials in 2024 after resolving FDA safety concerns that led to an initial application rejection in 2022. To date, 12 people globally have received the company's brain implant, accumulating over 15,000 hours of combined usage.

Current Applications:

The implant technology primarily targets individuals with conditions including spinal cord injuries and speech disabilities. The first patient has successfully used the device to perform various tasks such as playing video games, internet browsing, social media posting, and cursor control on a laptop.

Competitive Landscape:

Synchron Inc. is also developing competing brain-implant technology, testing its own device to assist people with motor impairments in computer-based typing.

Market Implications:

This advancement positions Neuralink at the forefront of the emerging brain-computer interface sector, with potential applications extending beyond assistive technology into broader neurotechnology markets. The FDA's expedited designation signals regulatory support for innovative medical devices addressing significant unmet needs in neurological care.